Advertisement
Advertisement
MenQuadfi

MenQuadfi

vaccine, meningococcal

Manufacturer:

Sanofi

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Meningococcal group A, C, W & Y conjugate vaccine
Indications/Uses
Active immunisation of individuals from 12 mth against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W & Y.
Dosage/Direction for Use
IM Primary vaccination Individual ≥12 mth 0.5 mL single dose. Booster vaccination 0.5 single dose in subject who previously received same serogroup-containing meningococcal vaccine.
Contraindications
Hypersensitivity to the vaccine or after previous inj.
Special Precautions
Hypersensitivity. Not to be administered SC, intravascularly or intradermally. Not as substitute for routine tetanus immunisation. Postpone vaccination in acute severe febrile illness. Syncope, other anxiety-related reactions; thrombocytopenia or any coagulation disorders. Immunodeficiency or immunocompromised patients. May affect ability to drive & use machines. Pregnancy & lactation. Paed <12 mth.
Adverse Reactions
Inj site pain, swelling, erythema; fever. Subjects ≥2 yr: Headache; myalgia; malaise. Subjects 12-23 mth: Loss of appetite; irritability; drowsiness; abnormal crying, inj site tenderness. Vomiting, diarrhoea.
Drug Interactions
Reduced immune response w/ immunosuppressive medicinal products. Consider separate administration w/ 13-valent pneumococcal polysaccharide conjugated vaccine in childn 12-23 mth at high risk for serogroup A disease.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07AH08 - meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated ; Belongs to the class of meningococcal bacterial vaccines.
Presentation/Packing
Form
MenQuadfi soln for inj (vial) 0.5 mL
Packing/Price
10 × 1's;1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement